Found 14 clinical trials
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
Patients with metastatic colorectal cancer (mCRC) who have received all approved standard treatments (except Regorafenib and TAS 102) no longer have treatment options available while maintaining a good performance status which would allow them to receive a new treatment
- 25 views
- 20 May, 2021
- 12 locations
Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer
The main purpose of study is to evaluate hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients with low and intermediate risk of progression prostate cancer.
- 4 views
- 23 Jan, 2021
- 1 location
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage
The purpose of this study is to To confirm the predictive value of CCND1 for TPF induction in cN2 patients with OSCC
- 19 views
- 24 Jan, 2021
- 1 location
Anastrozole Palbociclib Trastuzumab and Pertuzumab in HR-positive HER2-positive Metastatic Breast
and all biologic approach to the treatment of HR+, HER2+ metastatic breast cancer. Additionally, the researchers aim to examine potential biomarkers of response to palbociclib including cyclin D1
- 38 views
- 09 Jul, 2021
- 7 locations
A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer
biomarkers than those who receive placebo. Cyclin D1 will serve as the primary biomarker. This investigation will determine whether subjects randomized to UAB30 have an increase in all trans-retinoic
- 0 views
- 26 Jan, 2021
- 1 location
Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma
mechanisms have been described: (i) Amplification or overexpression of cyclin D1, (ii) Amplification of CDK4, (iii) Activating mutation of CDK4, and (iv) Loss of the CDK4 inhibitor, p16 (CDKN2A). Human
- 82 views
- 25 Jan, 2021
- 1 location
CDK4/6 Tumor Abemaciclib Paclitaxel
cancer cell proliferation. Cyclin D1 acts with CDK4 and CDK6 to phosphorylate Rb and promote cell-cycle progression, and CDK4/6 inhibitor might be effective for the patients with CCND1/2/3
- 0 views
- 01 May, 2021
- 1 location
A Study of Abemaciclib in Recurrent Glioblastoma
This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). The following intervention will be used in this study: -Abemaciclib
- 335 views
- 11 Aug, 2021
- 7 locations
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
This is a single-arm, phase II study that will enroll a total of 45 subjects. All subjects will have a confirmed diagnosis of metastatic or unresectable soft tissue sarcoma or bone sarcoma. All subjects must have intact Rb, identified at the time of screening, by immunohistochemistry testing of submitted tumor …
- 0 views
- 23 Feb, 2021
- 3 locations
Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer
This early phase I trial studies how well abemaciclib and letrozole work in treating patients with endometrial cancer and determines whether there are changes in patients' cancer cell biomarkers (a genetic feature or specific protein) for cell growth before and after treatment. Antihormone therapy with aromatase inhibitors, such as letrozole, …
- 2 views
- 15 May, 2021
- 2 locations
- 1
- 2